Your browser doesn't support javascript.
loading
Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.
Gleicher, Stephanie; Porter, Baylee A; Nath, Disharee; Li, Guanqun; Khanna, Rakesh; Goldberg, Hanan; Kortylewski, Marcin; Bratslavsky, Gennady; Kotula, Leszek.
Afiliación
  • Gleicher S; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Porter BA; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Nath D; Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Li G; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Khanna R; Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Goldberg H; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Kortylewski M; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Bratslavsky G; Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.
  • Kotula L; Beckman Research Institute, City of Hope, 1500 E. Duarte Road, Beckman Center Room 3111, Duarte, CA 91010, USA.
Cancers (Basel) ; 13(10)2021 May 17.
Article en En | MEDLINE | ID: mdl-34067832
Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay; however, some patients will transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC may develop symptomatic metastatic disease (mCRPC) and incur mortality several years later. Prior to metastatic disease, however, men acquire non-metastatic CRPC (nmCRPC) which lends the unique opportunity for intervention to delay disease progression and symptoms. This review addresses current therapies for nmCRPC, as well as novel therapeutics and pathway strategies targeting men with nmCRPC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza